Ternary copper (II) complex induced cell cycle arrest and apoptosis in human breast (MDA-MB-231) and colon (HT-29) cancer cells

Abstract

Event Abstract Back to Event Ternary copper (II) complex induced cell cycle arrest and apoptosis in human breast (MDA-MB-231) and colon (HT-29) cancer cells Jhi Biau Foo1*, Xian Wei Teo1, Zheng Yang Lee1, Chee Hong Leong1, Faris B. Norizan1, Sathiavani A. Arikrishnan2, Yin Sim Tor2, May Lee Low3 and Chew Hee Ng3 1 School of Pharmacy, Taylor's University, Faculty of Health and Medical Sciences, Malaysia 2 School of Biosciences, Taylor's University, Faculty of Health and Medical Sciences, Malaysia 3 International Medical University, Department of Pharmaceutical Chemistry, School of Pharmacy, Malaysia Background The use of copper complexes for cancer treatment has been widely explored as cancer cells are reported to take up greater amounts of copper than normal cells. Our previous study had successfully synthesised and characterised the Cu(phen)(L-tyr)Cl]·3H2O copper complex. Nevertheless, the mode of cell death induced by this copper complex against cancer cells remains unclear. Therefore, the current study investigated the mode of cell death induced by Cu(phen)(L-tyr)Cl]·3H2O against human breast and colon cancer cell lines. Methods The inhibitory and morphological changes induced by Cu(phen)(L-tyr)Cl]·3H2O against human breast (MDA-MB-231) and colon (HT-29) cancer cell lines were determined by the MTT assay and inverted light microscopy, respectively. Induction of cell cycle arrest and apoptosis were determined by flow cytometry analysis. Results The growth of cancer cell lines was inhibited by Cu(phen)(L-tyr)Cl]·3H2O in a dose- dependent manner with IC50 value of 3.5 µM against these two cancer cell lines. The copper complex was 9 and 1.5 folds more potent than cisplatin in inhibiting the growth of HT-29 colon and MDA-MB-231 breast cancer cells, respectively. It was found that Cu(phen)(L-tyr)Cl]·3H2O induced S phase cell cycle arrest on HT-29 colon and MDA-MB-231 breast cancer cells. Characteristics of apoptosis such as cellular shrinkage, membrane blebbing and apoptotic bodies were seen under inverted light microscope, indicating that Cu(phen)(L-tyr)Cl]·3H2O induced apoptosis in the cells. The observation was further ascertained using Annexin-V/PI flow cytometry analysis. Conclusion Our present study provided evidence regarding the anticancer effects and underlying mechanisms of Cu(phen)(L-tyr)Cl]·3H2O against human breast and colon cancer cells. These findings shed new light on the potential application of Cu(phen)(L-tyr)Cl]·3H2O as anticancer agent. Keywords: Copper Complex, Colon Cancer, breast cancer, Apoptosis, cell cycle arrest Conference: International Conference on Drug Discovery and Translational Medicine 2018 (ICDDTM '18) “Seizing Opportunities and Addressing Challenges of Precision Medicine”, Putrajaya, Malaysia, 3 Dec - 5 Feb, 2019. Presentation Type: Poster Presentation Topic: Cancer Citation: Foo J, Teo X, Lee Z, Leong C, Norizan FB, Arikrishnan SA, Tor Y, Low M and Ng C (2019). Ternary copper (II) complex induced cell cycle arrest and apoptosis in human breast (MDA-MB-231) and colon (HT-29) cancer cells. Front. Pharmacol. Conference Abstract: International Conference on Drug Discovery and Translational Medicine 2018 (ICDDTM '18) “Seizing Opportunities and Addressing Challenges of Precision Medicine”. doi: 10.3389/conf.fphar.2018.63.00135 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 09 Nov 2018; Published Online: 17 Jan 2019. * Correspondence: Dr. Jhi Biau Foo, School of Pharmacy, Taylor's University, Faculty of Health and Medical Sciences, Subang Jaya, Selangor Darul Ehsan, 47500, Malaysia, foojhibiau@gmail.com Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Jhi Biau Foo Xian Wei Teo Zheng Yang Lee Chee Hong Leong Faris B Norizan Sathiavani A Arikrishnan Yin Sim Tor May Lee Low Chew Hee Ng Google Jhi Biau Foo Xian Wei Teo Zheng Yang Lee Chee Hong Leong Faris B Norizan Sathiavani A Arikrishnan Yin Sim Tor May Lee Low Chew Hee Ng Google Scholar Jhi Biau Foo Xian Wei Teo Zheng Yang Lee Chee Hong Leong Faris B Norizan Sathiavani A Arikrishnan Yin Sim Tor May Lee Low Chew Hee Ng PubMed Jhi Biau Foo Xian Wei Teo Zheng Yang Lee Chee Hong Leong Faris B Norizan Sathiavani A Arikrishnan Yin Sim Tor May Lee Low Chew Hee Ng Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.